Prior to founding Define Ventures in 2019, Lynne Chou invested in digital health and connected devices for KPCB since 2013. She works alongside entrepreneurs to develop impactful technologies and therapies for improving patients’ lives.
Before joining KPCB, Lynne had over twelve years of healthcare operating and investing experience. She worked for eight years at Abbott Vascular and Guidant in multiple roles and worked on the launch of over ten interventional cardiology and cardiac surgery product families both in the US and internationally. Lynne also lead the global launch of Absorb, the world’s first bioresorbable vascular scaffold, recognized by WSJ as Medical Device Technology Innovation of the Year and Popular Mechanics. Lynne was responsible for building the global commercial strategy and therapy development as well as playing a key role in the clinical, reimbursement, operational strategy for the therapy.
Lynne earned her BS in industrial engineering from Stanford University and an MBA from Harvard Business School.